KELIM PSA as a Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated with ARPI

Basit Öğe Kaydı
dc.contributor.authorAtalah, Fatih
dc.contributor.authorKus, Fatih
dc.contributor.authorAcarbay, Aydin
dc.contributor.authorKarakok, Akgun
dc.contributor.authorAlkan, Onur
dc.contributor.authorNazli, Ismail
dc.contributor.authorOzilice, Utku
dc.date.accessioned2026-01-24T12:26:35Z
dc.date.available2026-01-24T12:26:35Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground/Objectives: Prostate cancer is a leading cause of cancer-related morbidity and mortality. While prostate-specific antigen (PSA) is crucial for monitoring, its static levels are limited in predicting outcomes precisely. The Kinetics of Elimination of PSA (KELIM PSA) has recently emerged as a dynamic biomarker of treatment response. This research sought to determine the predictive power of KELIM PSA in castration-resistant prostate cancer (CRPC) on androgen receptor pathway inhibitors (ARPI). Methods: This study retrospectively analyzed 98 CRPC patients treated with enzalutamide or abiraterone. The patients were categorized as either unfavorable (KELIM < 1) or favorable (KELIM >= 1). Demographic and clinical characteristics were compared, and survival outcomes were evaluated using Kaplan-Meier curves and Cox regression. Results: Of the cohort, 42 (42.9%) patients had favorable and 56 (57.1%) unfavorable KELIM values. The unfavorable group had a higher mortality rate (62.5% vs. 38.1%, p = 0.029). Univariate analysis showed that poor KELIM results increased mortality risk twofold (hazard ratio [HR]: 2.30, 95% confidence interval [CI]: 1.26-4.19, p = 0.006). In multivariable analysis, unfavorable KELIM remained independently associated with worse overall survival (HR: 2.09, 95% CI: 1.12-3.89, p = 0.020), together with second-line ARPI (HR: 3.19, 95% CI: 1.71-5.93, p < 0.001) and ADT + docetaxel during CSPC (HR: 2.14, 95% CI: 1.11-4.12, p = 0.022). Kaplan-Meier curves revealed that the unfavorable group had notably reduced overall survival and progression-free survival (log-rank p = 0.018). Conclusions: KELIM PSA is an independent predictor in ARPI-treated CRPC. By integrating PSA kinetics into prognostic models, risk stratification may be improved, and this may guide individualized treatment. Prospective multicenter validation is warranted.
dc.identifier.doi10.3390/jcm14228114
dc.identifier.issn2077-0383
dc.identifier.issue22
dc.identifier.pmid41303148
dc.identifier.scopus2-s2.0-105023062156
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/jcm14228114
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4773
dc.identifier.volume14
dc.identifier.wosWOS:001625682900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofJournal of Clinical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectARPI
dc.subjectcastration-resistant prostate cancer
dc.subjectKELIM PSA
dc.subjectprognosis
dc.subjectprostate cancer
dc.subjectPSA kinetics
dc.titleKELIM PSA as a Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated with ARPI
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu